December 09, 2024 2:44 PM EST | Source: Canadian Securities Exchange (CSE)
Toronto, Ontario–(Newsfile Corp. – December 9, 2024) – The Canadian Securities Exchange (“CSE” or “the Exchange”) today welcomed the listing of DiagnosTear Technologies Inc. (“DiagnosTear” or the “Company”). The Israel-based ophthalmic company recently completed an offering of subscription receipts, which converted into common shares and warrants prior to listing on the CSE. Its common shares were listed on the CSE today under the symbol DTR.
DiagnosTear is focused on the development and commercialization of disruptive diagnostic solutions for better management of eye diseases. The Company’s TeaRx™ technology is a diagnostic platform intended for rapid, point-of-care testing of ophthalmic pathologies through tear fluid. The Company is currently developing products for the diagnosis of Dry Eye Disease and Red Eye causes.
“The CSE has established…
